(Bloomberg) -- Sandoz Group AG plans to launch a semaglutide generic drug in Canada when the patent for the main ingredient ...

Sandoz Group said it would pay $275 million ... The case stems from allegations of price fixing of generic drugs in the U.S. The settlement includes the release of claims over alleged practices ...

with 500 million patients across more than 100 countries treated with Sandoz drugs. Generics and biosimilars account for an estimated 80% of medicines used worldwide by volume, at about 25% of the ...

Like rivals Teva Pharmaceutical Industries Ltd. and Viatris Inc., Sandoz copies branded drugs once they lose patent protection, which leads to reduced costs. It manufactures those products largely ...

Twenty U.S. states including California, Connecticut and Michigan have pushed back against a $10 million settlement that Florida reached with Swiss generic drugmaker Sandoz, saying a key provision ...

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal ...